Seladelpar: New hope for patients with primary biliary cholangitis

Yulia A Nevzorova; Francisco Javier Cubero

doi:10.1016/j.medj.2024.03.019

Seladelpar: New hope for patients with primary biliary cholangitis

Med. 2024 May 10;5(5):377-379. doi: 10.1016/j.medj.2024.03.019.

Authors

Yulia A Nevzorova¹, Francisco Javier Cubero²

Affiliations

¹ Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), Madrid, Spain; Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain.
² Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), Madrid, Spain; Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain. Electronic address: fcubero@ucm.es.

PMID: 38733969
DOI: 10.1016/j.medj.2024.03.019

Abstract

The study by Hirschfield et al.¹ demonstrated safety profile and clinically significant effectiveness of the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar in patients with primary biliary cholangitis, highlighting its plausible use as a second-line treatment to reduce disease activity and pruritus.

MeSH terms

Humans
Liver Cirrhosis, Biliary* / drug therapy
PPAR delta / agonists
PPAR delta / metabolism
Pruritus* / drug therapy

Substances

PPAR delta